Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hatchtech
Camberwell, Victoria, Australiahatchtech.com.au ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Xeglyze, a single-dose topical prescription treatment for head lice, has demonstrated high efficacy in clinical trials and received FDA approval in July 2020. It offers a single application solution that kills both lice and eggs without the need for combing or nit-picking.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculeTopical prescription product
- Industry
- Biotech
02
Partnerships
Dr Reddy’s Laboratories (acquirer/distributor/licensee of Xeglyze)
Beyond the preview
Go deeper on Hatchtech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hatchtech.